{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:01:16Z","timestamp":1789884076559,"version":"4.0.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":859,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1111\/bjd.12060","type":"journal-article","created":{"date-parts":[[2012,9,27]],"date-time":"2012-09-27T12:37:49Z","timestamp":1348749469000},"page":"1080-1087","source":"Crossref","is-referenced-by-count":83,"title":["A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis"],"prefix":"10.1093","volume":"168","author":[{"given":"J.P.","family":"Ortonne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Berardesca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Brault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,4,25]]},"reference":[{"key":"10.1111\/bjd.12060-BIB1|cit1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1529-8019.2007.00112.x","article-title":"Biological therapy and nail psoriasis","volume":"20","author":"Lawry","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1111\/bjd.12060-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.07.073","article-title":"Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy","volume":"57","author":"Jiaravuthisan","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12060-BIB3|cit3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000246274","article-title":"Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients","volume":"193","author":"De Jong","year":"1996","journal-title":"Dermatology"},{"issue":"Suppl. 1","key":"10.1111\/bjd.12060-BIB4|cit4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1468-3083.2009.03364.x","article-title":"Approach to managing patients with nail psoriasis","volume":"23","author":"Reich","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.12060-BIB5|cit5","first-page":"511","article-title":"Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis","volume":"53","author":"Leonard","year":"1978","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/bjd.12060-BIB6|cit6","volume-title":"The Nails in Disease","author":"Samman","year":"1994"},{"key":"10.1111\/bjd.12060-BIB7|cit7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/rheumatology\/keh198","article-title":"Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked","volume":"43","author":"Williamson","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/bjd.12060-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/j.1468-3083.2011.04289.x","article-title":"Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience","volume":"26","author":"Brazzelli","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.12060-BIB9|cit9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2230.2000.00663.x","article-title":"Management of nail psoriasis","volume":"25","author":"De Berker","year":"2000","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl. 2","key":"10.1111\/bjd.12060-BIB10|cit10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-3083.2011.03992.x","article-title":"Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis","volume":"25","author":"Maza","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 2","key":"10.1111\/bjd.12060-BIB11|cit11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1468-3083.2011.03993.x","article-title":"Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review","volume":"25","author":"Sbidian","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.12060-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/0190-9622(90)70356-M","article-title":"Effects of cyclosporine on renal function in psoriasis patients","volume":"23","author":"Messana","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12060-BIB13|cit13","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12060-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12060-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/bjd.12060-BIB16|cit16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12060-BIB17|cit17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3\u2003years: results from an open-label extension study for patients from REVEAL","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12060-BIB18|cit18","first-page":"683","article-title":"Etanercept in the treatment and retreatment of psoriasis in daily clinical practice","volume":"18","author":"Barrera","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1111\/bjd.12060-BIB19|cit19","doi-asserted-by":"crossref","first-page":"107928","DOI":"10.1155\/2011\/107928","article-title":"Dramatic response of nail psoriasis to infliximab","volume":"2011","author":"Safa","year":"2011","journal-title":"Case Report Med"},{"issue":"Suppl. 3","key":"10.1111\/bjd.12060-BIB20|cit20","first-page":"184","article-title":"Etanercept improves nail psoriasis","volume":"52","author":"Rich","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12060-BIB21|cit21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1468-3083.2010.03938.x","article-title":"Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy)","volume":"25","author":"S\u00e1nchez-Rega\u00f1a","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.12060-BIB22|cit22","first-page":"544","article-title":"Rapid response of nail psoriasis to etanercept","volume":"35","author":"Rallis","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1111\/bjd.12060-BIB23|cit23","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1468-3083.2009.03211.x","article-title":"Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis","volume":"23","author":"Luger","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.12060-BIB24|cit24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ard.2009.111856","article-title":"Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions","volume":"69","author":"Van den Bosch","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.12060-BIB25|cit25","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.12060-BIB26|cit26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1468-3083.2009.03453.x","article-title":"Treatment of nail psoriasis with adalimumab: an open label unblinded study","volume":"24","author":"Rigopoulos","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.12060-BIB27|cit27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jaad.2007.07.042","article-title":"Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1\u2003year","volume":"58","author":"Rich","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12060-BIB28|cit28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1529-8019.2012.01472.x","article-title":"Marked improvement in nail psoriasis during treatment with etanercept","volume":"24","author":"Gomez Vazquez","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1111\/bjd.12060-BIB29|cit29","doi-asserted-by":"crossref","DOI":"10.3109\/09546634.2011.646939","article-title":"Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study","author":"Kyriakou","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/bjd.12060-BIB30|cit30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/bjd.12060-BIB31|cit31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","article-title":"Current severe psoriasis and the rule of tens","volume":"152","author":"Finlay","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12060-BIB32|cit32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12060-BIB33|cit33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/009286150804200402","article-title":"Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials","volume":"42","author":"Mallinckrodt","year":"2008","journal-title":"Drug Inf J"},{"issue":"Suppl. 62","key":"10.1111\/bjd.12060-BIB34|cit34","first-page":"50","article-title":"Clinical meaning of change in Dermatology Life Quality Index scores","volume":"147","author":"Khilji","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12060-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12060-BIB36|cit36","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"BMJ"},{"key":"10.1111\/bjd.12060-BIB37|cit37","first-page":"1","article-title":"Nail psoriasis as a severity indicator: results from the PsoReal study","volume":"2","author":"Radtke","year":"2011","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1111\/bjd.12060-BIB38|cit38","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ad.2011.02.007","article-title":"[Nail psoriasis in individuals with psoriasis vulgaris: a study of 661 patients]","volume":"102","author":"Armesto","year":"2011","journal-title":"Actas Dermosifiliogr"},{"key":"10.1111\/bjd.12060-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/j.1365-4632.2006.02958.x","article-title":"The nail and Koebner-like phenomenon","volume":"45","author":"Daniel","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1111\/bjd.12060-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.12060","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.12060\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:03:00Z","timestamp":1676383380000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/168\/5\/1080\/6614313"}},"subtitle":["Effect of etanercept on nail psoriasis"],"short-title":[],"issued":{"date-parts":[[2013,4,25]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.12060","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4,25]]}}}